Literature DB >> 23329277

Modification of staging and treatment of head and neck cancer by FDG-PET/CT prior to radiotherapy.

A Abramyuk1, S Appold, K Zöphel, M Baumann, N Abolmaali.   

Abstract

BACKGROUND AND
PURPOSE: Reliable tumor staging is a fundamental pre-requisite for efficient tumor therapy and further prognosis. The aim of this study was to compare head and neck cancer (HNC) staging before and after FDG-PET/CT, evaluating the stage modifications for radiotherapy (RT) planning. PATIENTS AND METHODS: A total of 102 patients with untreated primary HNC, who underwent conventional staging and staging including FDG-PET/CT before RT, were enrolled in this retrospective study. Blinded pre-FDG-PET/CT and post-FDG-PET/CT staging data were compared. The impact on patient management was tested by comparing the intention before and after FDG-PET/CT.
RESULTS: Significant modifications of T, N, and M stage as well as clinical stage were detected after inclusion of FDG-PET/CT data (p = 0.002, 0.0006, 0.001, 0.03, respectively). Overall, the implementation of FDG-PET/CT led to modification of RT intention decision in 14 patients.
CONCLUSIONS: FDG-PET/CT demonstrates essential influence on tumor staging in HNC patients scheduled for irradiation. Implementation of FDG-PET/CT in imaging protocol improves selection of candidates for curative and palliative RT and allows further optimization of treatment management and therapy intention.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23329277     DOI: 10.1007/s00066-012-0283-0

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  33 in total

Review 1.  Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT : part 1.

Authors:  Kerstin A Brocker; Celine D Alt; Michael Eichbaum; Christof Sohn; Hans-Ulrich Kauczor; Peter Hallscheidt
Journal:  Strahlenther Onkol       Date:  2011-09-23       Impact factor: 3.621

Review 2.  PET/CT in non-small cell lung cancer staging-promises and problems.

Authors:  A Devaraj; G J R Cook; D M Hansell
Journal:  Clin Radiol       Date:  2007-02       Impact factor: 2.350

3.  Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI.

Authors:  T Stuckensen; A F Kovács; S Adams; R P Baum
Journal:  J Craniomaxillofac Surg       Date:  2000-12       Impact factor: 2.078

4.  Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer.

Authors:  Maria Hentschel; Steffen Appold; Andreas Schreiber; Nasreddin Abolmaali; Andrij Abramyuk; Wolfgang Dörr; Joerg Kotzerke; Michael Baumann; Klaus Zöphel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-25       Impact factor: 9.236

5.  Comparison of radiochemotherapy alone to surgery plus radio(chemo)therapy for non-metastatic stage III/IV squamous cell carcinoma of the head and neck: A matched-pair analysis.

Authors:  Dirk Rades; Thekla Meyners; Nadja Kazic; Amira Bajrovic; Volker Rudat; Steven E Schild
Journal:  Strahlenther Onkol       Date:  2011-08-16       Impact factor: 3.621

6.  Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging.

Authors:  Christopher Scarfone; William C Lavely; Anthony J Cmelak; Dominique Delbeke; William H Martin; Dean Billheimer; Dennis E Hallahan
Journal:  J Nucl Med       Date:  2004-04       Impact factor: 10.057

7.  Accuracy of 18F-FDG-PET/CT for staging of oral squamous cell carcinoma.

Authors:  Monica Pentenero; Angela Cistaro; Mario Brusa; Maria Maddalena Ferraris; Carla Pezzuto; Riccardo Carnino; Edro Colombini; Maria Consuelo Valentini; Luca Giovanella; Giuseppe Spriano; Sergio Gandolfo
Journal:  Head Neck       Date:  2008-11       Impact factor: 3.147

8.  PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.

Authors:  Zohar Keidar; Nissim Haim; Luda Guralnik; Mirjana Wollner; Rachel Bar-Shalom; Alon Ben-Nun; Ora Israel
Journal:  J Nucl Med       Date:  2004-10       Impact factor: 10.057

9.  A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer.

Authors:  Trevor Leong; Craig Everitt; Kally Yuen; Sara Condron; Andrew Hui; Samuel Y K Ngan; Alexander Pitman; Eddie W F Lau; Michael MacManus; David Binns; Trevor Ackerly; Rodney J Hicks
Journal:  Radiother Oncol       Date:  2006-03-20       Impact factor: 6.280

Review 10.  Staging and prognosis in head and neck cancer.

Authors:  Marc P van der Schroeff; Robert J Baatenburg de Jong
Journal:  Oral Oncol       Date:  2008-08-19       Impact factor: 5.337

View more
  12 in total

Review 1.  The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature.

Authors:  Giovanni Cammaroto; Natale Quartuccio; Alessandro Sindoni; Francesca Di Mauro; Federico Caobelli
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-14       Impact factor: 2.503

2.  Influence of experience and qualification on PET-based target volume delineation. When there is no expert--ask your colleague.

Authors:  C Doll; V Duncker-Rohr; G Rücker; M Mix; M MacManus; D De Ruysscher; W Vogel; J G Eriksen; W Oyen; A-L Grosu; W Weber; U Nestle
Journal:  Strahlenther Onkol       Date:  2014-03-11       Impact factor: 3.621

3.  18F-fluorodeoxyglucose positron emission tomography for predicting tumor response to radiochemotherapy in nasopharyngeal carcinoma.

Authors:  Meng Su; Liang Zhao; Hangping Wei; Ruifang Lin; Xuebang Zhang; Changlin Zou
Journal:  Strahlenther Onkol       Date:  2015-05-17       Impact factor: 3.621

4.  Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial.

Authors:  V Budach; E-T Becker; D Boehmer; H Badakhshi; U Jahn; K-D Wernecke; C Stromberger
Journal:  Strahlenther Onkol       Date:  2013-12-11       Impact factor: 3.621

5.  Asphericity of pretherapeutic tumour FDG uptake provides independent prognostic value in head-and-neck cancer.

Authors:  Ivayla Apostolova; Ingo G Steffen; Florian Wedel; Alexandr Lougovski; Simone Marnitz; Thorsten Derlin; Holger Amthauer; Ralph Buchert; Frank Hofheinz; Winfried Brenner
Journal:  Eur Radiol       Date:  2014-06-26       Impact factor: 5.315

6.  Positron emission tomography and stage migration in head and neck cancer.

Authors:  Noam A VanderWalde; Ramzi G Salloum; Tsai-Ling Liu; Mark C Hornbrook; Maureen C O'Keeffe Rosetti; Debra P Ritzwoller; Paul A Fishman; Jennifer Elston Lafata; Amir H Khandani; Bhishamjit S Chera
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-07       Impact factor: 6.223

7.  Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy.

Authors:  Matthias F Haefner; Kristin Lang; David Krug; Stefan A Koerber; Lorenz Uhlmann; Meinhard Kieser; Juergen Debus; Florian Sterzing
Journal:  J Radiat Res       Date:  2015-04-23       Impact factor: 2.724

Review 8.  Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm.

Authors:  Ramasamy Paulmurugan; Bryan Oronsky; Chad F Brouse; Tony Reid; Susan Knox; Jan Scicinski
Journal:  Theranostics       Date:  2013-05-25       Impact factor: 11.556

9.  Image-guided radiotherapy for locally advanced head and neck cancer.

Authors:  Nam P Nguyen; Sarah Kratz; Claire Lemanski; Jacqueline Vock; Vincent Vinh-Hung; Alexander Chi; Fabio Almeida; Michael Betz; Rihan Khan; Juan Godinez; Ulf Karlsson; Fred Ampil
Journal:  Front Oncol       Date:  2013-07-08       Impact factor: 6.244

10.  FDG-PET/CT imaging for tumor staging and definition of tumor volumes in radiation treatment planning in non-small cell lung cancer.

Authors:  Yuanda Zheng; Xiaojiang Sun; Jian Wang; Lingnan Zhang; Xiaoyun DI; Yaping Xu
Journal:  Oncol Lett       Date:  2014-02-12       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.